CubaseBio is building a next-generation 3D spatial transcriptomics platform that captures gene expression inside intact specimens through volumetric DNA microscopy. The technology reconstructs three-dimensional proximity maps by embedding molecular networks into samples and decoding them with DNA sequencing, yielding both spatial coordinates and nucleotide-level information in a single readout. By moving beyond traditional 2D tissue sections, the company aims to make spatial biology workflows scalable for drug discovery, disease research, organoid studies and whole-organism profiling. Founded in 2024 by spatial-omics veterans Malte Kuhnemund, Xiaoyan Qian, Toon Verheyen and Paulius Mielinis, the team also includes scientific advisory co-founders Joshua Weinstein and Björn Högberg, pioneers of DNA microscopy. CubaseBio plans to use its newly raised capital to advance core technology development, expand engineering capacity and initiate early commercialization efforts. Financially, the company has secured €5.9 million in blended funding, its first external capital, providing runway to refine the platform and engage pilot customers. No user, revenue or deployment metrics have been disclosed yet.

Total raised

$7M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2026